| CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old (NCT04269213) | Roswell Park Cancer Institute | 2021-07-29 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation (NCT03602898) | Fred Hutchinson Cancer Center | 2021-06-01 |
| TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia (NCT04518345) | Uma Borate | 2020-11-05 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies (NCT03272633) | Rutgers, The State University of New Jersey | 2020-10-26 |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting (NCT04128501) | M.D. Anderson Cancer Center | 2020-05-05 |
| AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission (NCT04062266) | M.D. Anderson Cancer Center | 2019-09-13 |
| A Post-Marketing Observational Study of VYXEOS™ (NCT03526926) | Jazz Pharmaceuticals | 2018-10-23 |
| Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (NCT03330821) | University of Southern California | 2018-04-18 |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia (NCT03009240) | City of Hope Medical Center | 2017-08-21 |
| Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia (NCT03226418) | University of Nebraska | 2017-07-07 |
| Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (NCT02658487) | Vanderbilt-Ingram Cancer Center | 2016-03-01 |
| Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations (NCT02323607) | Bhavana Bhatnagar | 2016-01-12 |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (NCT02397720) | M.D. Anderson Cancer Center | 2015-04-07 |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia (NCT01904136) | M.D. Anderson Cancer Center | 2014-04-22 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies (NCT01823198) | M.D. Anderson Cancer Center | 2013-06-11 |
| NK Cells in Cord Blood Transplantation (NCT01619761) | M.D. Anderson Cancer Center | 2013-05-03 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia (NCT01420926) | National Cancer Institute (NCI) | 2011-11-16 |
| Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia (NCT01253070) | National Cancer Institute (NCI) | 2011-04-01 |
| Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01238211) | National Cancer Institute (NCI) | 2010-12-14 |
| Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT01130506) | National Cancer Institute (NCI) | 2010-05-17 |